

Press Release

Granules India's Revenue increases 11% to Rs. 346 Cr.; Net Profit surges 19% to Rs. 27 Cr.

Hyderabad, July 23, 2015: Granules India Ltd., a fast growing pharmaceutical manufacturing company, announced financial results for its First Quarter ended 30th June, 2015.

Consolidated Q1FY16 Financial Highlights

- Revenue: Rs. 346 Cr., an increase of 11% compared to Rs. 311 Cr. in Q1FY15
- EBITDA: Rs. 64 Cr., an increase of 20% compared to Rs. 53 Cr. in Q1FY15
- Net Profit: Rs. 27 Cr., an increase of 19% compared to Rs. 23 Cr. in Q1FY15

The Company's profitability margins continued to strengthen compared to the corresponding quarter in the previous financial year and sequential quarter. The Company's focus on operational efficiency helped improved EBITDA margin by 137 basis points compared to the Q1FY15. During this quarter PAT margin has also witnessed an improvement of 50 basis points compared to the same period previous year.

The Company's standalone sales during the quarter were Rs. 325 Cr., an increase of 28% from the same quarter previous year. EBITDA and PAT increased by 33% and 36% to Rs. 66 Cr. and Rs. 30 Cr. compared to Q1FY15.

The Board of Directors has approved the issue of 1,86,56,000 warrants on preferential basis to M/s. Tyche Technologies Pvt. Ltd., a promoter group Company, subject to approval of the shareholders, at a price arrived at in accordance with the SEBI (ICDR) Regulations, 2009.

“The first quarter of the financial year of 2016 had been encouraging as we continued to deliver strong results by focussing on operational efficiency and showing improvement in margin profile of the Company. During this quarter, we have further strengthened our footings towards introduction of newer molecules to increase our product portfolio. In addition, our PFI expansion at the Gagillapur facility with 4000 TPA has successfully completed trial runs and we expect to ramp up production in that block throughout the year.” said Mr. C Krishna Prasad, Chairman & Managing Director of Granules India.



About Granules India Ltd.

(BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

Granules has the largest PFI facility in the world with an industry leading 6 ton batch size. The Company has its own ANDAs and dossiers which enable customers to quickly enter a market instead of filing their own applications. Granules has a highly skilled regulatory affairs department that can offer customers support and can help them navigate through regulatory issues.

Granules has strengthened its advantages through its Operational Excellence (OE) department which looks at every step of the manufacturing process in order to gain efficiencies and has also implemented systems that have standardized quality and reduced variation. The Company's OE program is regularly cited by MNCs as a "best in class" program and is the comparative advantage that lets Granules provide world-class quality products at a lower cost than its competitors. The adoption of the OE philosophy by Granules has earned it several recognitions including The Economic Times Manufacturing Excellence Awards 2011.

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

Contacts:

Govindan JM
Genesis Burson-Marsteller
+91 9703700884
Govindan.JM@bm.com

Appendix

PART I					(Rs in Lakhs)
Statement of Consolidated Un-Audited Results for the Quarter ended June 30, 2015					
SI No.	Particulars	Quarter ended			Year ended
		30.06.2015 Un-Audited	31.03.2015 Audited	30.06.2014 Un-Audited	31.03.2015 Audited
1	Income from Operations				
	(a) Net sales / Income from Operations (Net of Excise duty)	34,593.90	35,460.16	31,102.08	1,29,292.24
	(b) Other operating income	-	-	-	-
	Total Income from operations (net)	34,593.90	35,460.16	31,102.08	1,29,292.24
2	Expenses				
	(a) Cost of material Consumed	19,894.11	22,030.65	17,358.57	76,942.80
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in Inventories of Finished goods, Work in progress and Stock-in-trade	(1,243.81)	(18.18)	712.77	(2,247.68)
	(d) Employee Benefits Expense	3,072.95	2,571.24	2,595.60	10,695.78
	(e) Depreciation and Amortisation expense	1,470.44	1,431.90	1,167.17	5,265.10
	(f) Manufacturing Expenses	2,657.61	2,164.17	1,975.12	8,873.31
	(g) Freight outward & clearing charges	1,218.74	1,304.91	1,271.32	5,098.29
	(h) R & D Expenses	458.00	750.97	75.32	960.96
	(i) Other expenditure	2,355.57	1,755.47	1,832.67	8,107.36
	Total expenses	29,883.61	31,991.12	26,988.54	1,13,695.91
3	Profit from Operations before Other Income, Finance costs & Exceptional Items (1 - 2)	4,710.29	3,469.04	4,113.54	15,596.33
4	Other Income	212.68	251.29	41.98	434.31
5	Profit from Ordinary activities before Finance costs and exceptional items (3 + 4)	4,922.97	3,720.33	4,155.52	16,030.63
6	Finance Costs	831.10	796.68	742.63	3,234.60
7	Profit from Ordinary activities after Finance costs but before exceptional items (5 - 6)	4,091.87	2,923.65	3,412.89	12,796.04
8	Exceptional items	-	-	-	-
9	Profit from Ordinary activities before Tax (7 + 8)	4,091.87	2,923.65	3,412.89	12,796.04
10	Tax expense	1,376.89	683.93	1,126.23	3,705.25
11	Net Profit from ordinary activities after tax (9 - 10)	2,714.98	2,239.72	2,286.66	9,090.78
12	Extraordinary items (net of tax expense)	-	-	-	-
13	Net Profit for the period (11 + 12)	2,714.98	2,239.72	2,286.66	9,090.78
14	Paid-up share capital (Face Value of Re.1/- per share)	2,047.62	2,042.52	2,035.62	2,042.52
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				41,073.83
16	Earnings per Share (face value of Re. 1/- each) (not annualised)				
	(a) Basic (in Rs.)	1.33	1.10	1.13	4.46
	(b) Diluted (in Rs)	1.32	1.09	1.10	4.41

PART II					
Select Information for the Quarter ended June 30, 2015					
SI No.	Particulars	Quarter ended			Year ended
		30.06.2015	31.03.2015	30.06.2014	31.03.2015
A					
1	Public Shareholding				
	- No. of shares	10,55,14,340	10,50,04,340	1,04,34,688	10,50,04,340
	- Percentage of shareholding	51.53%	51.41%	51.26%	51.41%
2	Promoters and promoter group shareholding				
	a) Pledged/Encumbered				
	Number of shares	1,12,77,585	1,50,43,300	15,04,330	1,50,43,300
	Percentage of shares to promoter and promoter group	11.36%	15.16%	15.16%	15.16%
	Percentage of shares to total share capital	5.51%	7.37%	7.39%	7.37%
	b) Non-encumbered				
	Number of shares	8,79,69,615	8,42,03,900	84,17,136	8,42,03,900
	Percentage of shares to promoter and promoter group	88.64%	84.84%	84.84%	84.84%
	Percentage of shares to total share capital	42.96%	41.22%	41.35%	41.22%

SI No.	Particulars	Quarter ended 30.06.2015
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the Quarter	NIL
	Received during the quarter	58
	Disposed of during the quarter	56
	Remaining unresolved at the end of the quarter	2

- The Un-Audited consolidated financial results for the quarter ended 30th June, 2015 have been reviewed by the Audit Committee of the Board on 22nd July, 2015 and approved by the Board of Directors at its meeting held on 23rd July, 2015.
- The Auditors of the Company carried out Limited Review of the financial results for the quarter ended 30th June, 2015.
- The subsidiaries and Joint Venture companies considered for the consolidated financial statement as on 30th June, 2015 are Granules USA Inc, GIL Life Sciences Pvt Ltd, Granules Pharma Inc., (Subsidiaries) and Granules Biocause Pharmaceutical Co., Ltd., and Granules Omnichem Pvt Ltd (50% Joint Venture Companies).
- Pursuant to the Notification No.G.S.R.913(E), dt.29.12.2011 issued by the Ministry of Corporate Affairs, the company has opted to capitalise foreign currency gains and losses on loans utilised for purchase of fixed assets.
- During the quarter loss of Rs.241.47 lakhs (Gain of Rs.108.01 Lakhs for the Quarter ended 30th June, 2014) was transferred to fixed assets.
- The consolidated financial results are prepared in accordance with Accounting Standards 21 and 27.
- As per clause 41 of the listing agreement, the Company has opted to publish only consolidated financial results. The stand-alone financial results are available for perusal on the Company's website as well as on the stock exchanges' websites as stated below:
www.granulesindia.com, www.bseindia.com and www.nse-india.com
- The Company operates only in the segment of Pharmaceuticals.
- The Company during the current quarter has allotted 5,10,000 equity shares of Re. 1/- each, fully paid up on exercise of options by employees / Directors in accordance with the Company's Employee Stock Option Scheme(s).
- Standalone Results as on 30.06.2015 are as under -

Particulars	Quarter ended			Year ended
	30.06.2015 Un-Audited	31.03.2015 Audited	30.06.2014 Un-Audited	31.03.2015 Audited
Net Sales/Income from Operations	32,532.04	31,721.60	25,344.90	1,21,331.13
Profit Before Tax	4,385.63	3,570.70	3,315.03	13,225.94
Profit After Tax	3,034.67	2,851.65	2,234.94	9,522.64

10) Previous period / year figures have been regrouped, wherever necessary.

for and on behalf of the Board

PART I		Statement of Standalone Un-Audited Results for the quarter ended June 30, 2015				(Rs.in lakhs)
SI No.	Particulars	Quarter ended			Year ended	
		30.06.2015	31.03.2015	30.06.2014	31.03.2015	
		Un-Audited	Audited	Un-Audited	Audited	
1	Income from Operations					
	(a) Net sales / Income from Operations (Net of Excise duty)	32,532.04	31,721.60	25,344.90	1,21,331.13	
	(b) Other operating income	-	-	-	-	
	Total Income from operations (net)	32,532.04	31,721.60	25,344.90	1,21,331.13	
2	Expenses					
	(a) Cost of material Consumed	18,419.04	17,758.98	14,490.67	71,777.12	
	(b) Purchases of stock-in-trade	-	-	-	-	
	(c) Changes in Inventories of Finished goods, Work in progress and Stock-in-trade	(603.74)	941.29	(85.14)	(1,056.18)	
	(d) Employee Benefits Expense	2,575.46	2,126.82	1,830.12	8,923.21	
	(e) Depreciation and Amortisation expense	1,391.06	1,337.30	965.74	4,955.87	
	(f) Manufacturing Expenses	2,179.56	1,836.49	1,382.10	7,526.40	
	(g) Freight outward & clearing charges	1,162.15	1,283.36	1,207.63	4,993.25	
	(h) R & D Expenses	423.13	715.82	46.92	840.39	
	(i) Other expenditure	1,954.99	1,558.48	1,568.11	7,348.50	
	Total expenses	27,501.65	27,558.55	21,406.15	1,05,308.57	
3	Profit from Operations before Other Income, Finance costs & Exceptional Items (1- 2)	5,030.39	4,163.05	3,938.76	16,022.56	
4	Other Income	162.58	141.66	31.38	296.32	
5	Profit from Ordinary activities before Finance costs and exceptional items (3 - 4)	5,192.97	4,304.71	3,970.14	16,318.88	
6	Finance Costs	807.34	734.00	655.10	3,092.94	
7	Profit from Ordinary activities after Finance costs but before exceptional items (5 - 6)	4,385.63	3,570.70	3,315.03	13,225.94	
8	Exceptional items	-	-	-	-	
9	Profit from Ordinary activities before Tax (7 + 8)	4,385.63	3,570.70	3,315.03	13,225.94	
10	Tax expense	1,350.96	719.05	1,080.09	3,703.30	
11	Net Profit from ordinary activities after tax (9 - 10)	3,034.67	2,851.65	2,234.94	9,522.64	
12	Extraordinary items (net of tax expense)	-	-	-	-	
13	Net Profit for the period (11 + 12)	3,034.67	2,851.65	2,234.94	9,522.64	
14	Paid-up share capital (Face Value of Re.1/- per share)	2,047.62	2,042.52	2,035.62	2,042.52	
15	Reserves excluding Revaluation Reserve as per balance sheet of previous Accounting Year				40,498.41	
16	Earnings per Share (Face value Re. 1/- each) (not Annualised)					
	(a) Basic (in Rs.)	1.49	1.40	1.10	4.67	
	(b) Diluted (in Rs)	1.47	1.38	1.08	4.62	

PART II		Select Information for the quarter ended June 30, 2015			
SI No.	Particulars	Quarter ended			Year ended
		30.06.2015	31.03.2015	30.06.2014	31.03.2015
A					
1	Public Shareholding				
	- No. of shares	10,55,14,340	10,50,04,340	1,04,34,688	10,50,04,340
	- Percentage of shareholding	51.53%	51.41%	51.26%	51.41%
2	Promoters and promoter group shareholding				
	a) Pledged/Encumbered				
	Number of shares	1,12,77,585	1,50,43,300	15,04,330	1,50,43,300
	Percentage of shares to promoter and promoter group	11.36%	15.16%	15.16%	15.16%
	Percentage of shares to total share capital	5.51%	7.37%	7.39%	7.37%
	b) Non-encumbered				
	Number of shares	8,79,69,615	8,42,03,900	84,17,136	8,42,03,900
	Percentage of shares to promoter and promoter group	88.64%	84.84%	84.84%	84.84%
	Percentage of shares to total share capital	42.96%	41.22%	41.35%	41.22%

SI No.	Particulars	Quarter ended 30.06.2015
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the Quarter	NIL
	Received during the quarter	58
	Disposed of during the quarter	56
	Remaining unresolved at the end of the quarter	02

- The Un-Audited financial results for the quarter ended 30th June, 2015 have been reviewed by the Audit Committee of the Board on 22nd July, 2015 and approved by the Board of Directors at its meeting held on 23rd July, 2015.
- The Auditors of the Company carried out Limited Review of the financial results for the quarter ended 30th June, 2015.
- Pursuant to the Notification No.G.S.R.913(E), dt.29.12.2011 issued by the Ministry of Corporate Affairs, the company has opted to capitalise foreign currency gains and losses on loans utilised for purchase of fixed assets.
- During the quarter, loss of Rs.241.47 lakhs (Gain of Rs.108.01 Lakhs for the Quarter ended 30 June 2014) was transferred to fixed assets.
- The current quarter numbers are not comparable with the corresponding quarter of previous year, due to merger of Auctus Pharma Limited, pursuant to the approval of Scheme of Amalgamation by the Hon'ble High Court of Judicature at Hyderabad for the State of Telangana and the State of Andhra Pradesh vide its order dated September 23, 2014, with the Company during third quarter of FY 2014-15 with appointed date 1.4.2013.
- As per clause 41 of the listing agreement, the Company has opted to publish only consolidated financial results. The stand-alone financial results are available for perusal on the Company's website as well as on the stock exchanges' websites as stated below:
www.granulesindia.com, www.bseindia.com and www.nse-india.com
- The Company operates only in the segment of Pharmaceuticals.
- The Company during the current quarter has allotted 5,10,000 equity shares of Re. 1/- each, fully paid up on exercise of options by employees / Directors in accordance with the Company's Employee Stock Option Scheme(s).
- Previous periods / years figures have been regrouped, wherever necessary.

for and on behalf of the Board